|Awarded On||June 18, 2010|
|Title||Cancer Treatment Including Drug Discovery/Development and Clinical Trials|
|Program||Product Development Research|
|Award Mechanism||Company Commercialization|
|Institution/Organization||Mirna Therapeutics, Inc.|
|Principal Investigator/Program Director||Ana Ward|
|Cancer Sites||Basic Science, Multiple Sites|
Mirna Therapeutics, Inc. (Mirna) is a discovery-stage biotechnology research and development company focused on microRNA-directed oncology therapies. MicroRNAs (miRNAs) are approximately 21 nucleotides long and affect gene expression by interacting with messenger RNAs. Misregulation of miRNAs appears to play a fundamental role in many cancers and unique miRNA profiles have been identified that are useful for diagnosis of certain cancer types. Mirna’s lead cancer programs feature MicroRNA Replacement Therapy" which involves introducing tumor suppressor miRNAs into cancer cells to induce cell death and tumor shrinkage. The Company has a substantial body of pending intellectual property a..."